EBS
Emergent BioSolutions Inc. NYSE Listed Nov 15, 2006$9.13
Mkt Cap $471.3M
52w Low $5.31
43.7% of range
52w High $14.06
50d MA $8.42
200d MA $9.63
P/E (TTM)
8.6x
EV/EBITDA
4.9x
P/B
0.9x
Debt/Equity
1.1x
ROE
10.1%
P/FCF
4.2x
RSI (14)
—
ATR (14)
—
Beta
2.36
50d MA
$8.42
200d MA
$9.63
Avg Volume
843.9K
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
400 Professional Drive · Gaithersburg, MD 20879 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.25 | 0.21 | +184.0% | 8.23 | +9.2% | +2.9% | +3.8% | +10.0% | +10.6% | +10.9% | — |
| Feb 26, 2026 | AMC | 0.11 | -0.43 | -490.9% | 11.10 | -26.1% | -26.6% | -19.0% | -19.6% | -21.0% | -24.0% | — |
| Oct 29, 2025 | AMC | -0.12 | 1.06 | +983.3% | 9.40 | +15.5% | +36.6% | +32.8% | +11.6% | +7.3% | +10.0% | — |
| Aug 6, 2025 | AMC | -0.26 | 0.16 | +161.5% | 6.03 | +8.5% | +36.7% | +42.1% | +35.3% | +47.8% | +45.8% | — |
| May 7, 2025 | AMC | 0.49 | 0.71 | +44.9% | 4.74 | +14.6% | +34.2% | +19.2% | +23.2% | +24.1% | +19.0% | — |
| Mar 3, 2025 | AMC | -0.35 | 0.05 | +114.3% | 6.83 | -18.6% | -6.4% | -15.1% | -14.5% | -15.5% | -17.7% | — |
| Nov 6, 2024 | AMC | 0.49 | 1.37 | +179.6% | 9.20 | +24.2% | +19.6% | +27.9% | +30.1% | +18.4% | +8.4% | — |
| Aug 6, 2024 | AMC | -0.97 | -2.32 | -139.2% | 9.86 | -35.5% | -42.0% | -14.8% | -28.1% | -32.4% | -31.2% | — |
| May 1, 2024 | AMC | -0.86 | 0.59 | +168.6% | 1.93 | +52.8% | +71.0% | +101.6% | +106.2% | +128.0% | +128.5% | — |
| Mar 6, 2024 | AMC | -0.33 | -0.77 | -133.3% | 3.26 | -16.3% | -15.0% | -17.5% | -14.1% | -28.5% | -31.3% | — |
| Dec 11, 2023 | AMC | -0.12 | -1.44 | -1100.0% | 2.12 | +0.0% | -1.4% | +8.0% | +19.3% | +12.3% | +10.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.29 | $8.20 | -1.1% | +0.7% | +1.2% | -1.3% | -1.9% | -2.7% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.33 | $12.25 | -0.6% | -1.1% | -1.0% | -0.2% | +0.7% | +3.9% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.21 | $8.20 | -0.1% | -4.6% | -7.1% | -7.7% | -7.9% | +0.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.86 | $4.82 | -0.8% | -2.5% | +6.4% | -0.6% | -7.0% | -8.6% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.73 | $5.69 | -0.7% | -0.2% | +0.0% | -4.0% | -9.8% | -14.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $5.56 | -18.6% | -6.4% | -15.1% | -14.5% | -15.5% | -17.7% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.88 | $9.97 | +0.9% | +3.4% | +10.0% | +16.2% | +18.0% | +13.3% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.09 | $9.82 | -2.7% | -2.1% | -6.7% | -7.2% | -5.6% | -1.2% |
| Nov 7 | Benchmark | Maintains | Buy → Buy | — | $9.20 | $11.43 | +24.2% | +19.6% | +27.9% | +30.1% | +18.4% | +8.4% |
| Sep 13 | Rodman & Renshaw | Maintains | Buy → Buy | — | $7.63 | $7.56 | -0.9% | +3.1% | -5.0% | -9.8% | -9.6% | -8.4% |
| Aug 16 | Benchmark | Maintains | Buy → Buy | — | $8.66 | $10.00 | +15.5% | +24.0% | +39.7% | +11.3% | +21.1% | +9.7% |
| Aug 9 | Benchmark | Maintains | Buy → Buy | — | $8.40 | $8.32 | -1.0% | -15.6% | -20.6% | -19.3% | -9.9% | +3.1% |
| Jul 3 | Benchmark | Maintains | Buy → Buy | — | $7.49 | $7.62 | +1.7% | +0.7% | +5.9% | +8.5% | +16.4% | +24.2% |
| Jul 2 | Benchmark | Maintains | Buy → Buy | — | $7.06 | $7.28 | +3.1% | +6.1% | +6.8% | +12.3% | +15.2% | +23.5% |
| Jun 24 | Benchmark | Maintains | Buy → Buy | — | $6.52 | $6.48 | -0.6% | +3.8% | +5.7% | +0.6% | +7.1% | +4.6% |
| Jun 21 | Benchmark | Maintains | Buy → Buy | — | $6.47 | $6.54 | +1.1% | +0.8% | +4.6% | +6.5% | +1.4% | +7.9% |
| Jun 20 | Benchmark | Maintains | Buy → Buy | — | $6.06 | $6.23 | +2.8% | +6.8% | +7.6% | +11.7% | +13.7% | +8.3% |
| Apr 11 | Benchmark | Maintains | Buy → Buy | — | $2.23 | $2.24 | +0.4% | -1.8% | -7.6% | -11.2% | -12.6% | -14.8% |
| Mar 7 | Benchmark | Upgrade | Hold → Buy | — | $3.26 | $2.73 | -16.3% | -15.0% | -17.5% | -14.1% | -28.5% | -31.3% |
| Aug 29 | Benchmark | Downgrade | Buy → Hold | — | $4.42 | $4.21 | -4.8% | -7.9% | +2.7% | +6.1% | +14.9% | +9.0% |
| May 31 | Benchmark | Maintains | Buy → Buy | — | $8.22 | $8.22 | +0.0% | +3.8% | -0.2% | +0.2% | -3.8% | -2.6% |
| May 19 | Benchmark | Maintains | Buy → Buy | — | $8.64 | $8.64 | +0.0% | -5.4% | -0.8% | +1.2% | -2.5% | -5.7% |
| Apr 10 | Benchmark | Upgrade | Hold → Buy | — | $10.56 | $11.15 | +5.6% | +17.2% | +25.1% | +17.3% | +19.5% | +12.2% |
| Mar 17 | JP Morgan | Downgrade | Neutral → Underweight | — | $9.65 | $8.80 | -8.8% | -15.9% | -16.4% | -15.3% | -19.3% | -18.5% |
| Nov 10 | Benchmark | Downgrade | Buy → Hold | — | $12.85 | $13.49 | +5.0% | +16.7% | +22.5% | +4.7% | +3.6% | -5.1% |
| Nov 9 | Chardan Capital | Maintains | Buy → Buy | — | $19.73 | $17.39 | -11.9% | -34.9% | -24.0% | -20.2% | -31.8% | -32.5% |
| Sep 12 | Cowen & Co. | Maintains | Market Perform → Market Perform | — | $25.07 | $25.10 | +0.1% | -0.1% | -8.8% | -9.4% | -8.0% | -8.5% |
| May 4 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $33.37 | $33.09 | -0.8% | +1.4% | -3.3% | -5.7% | -8.1% | -8.9% |
| Apr 29 | Chardan Capital | Maintains | Buy → Buy | — | $36.61 | $34.61 | -5.5% | -11.6% | -7.7% | -8.8% | -7.5% | -11.8% |
| Mar 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $42.20 | $41.87 | -0.8% | -6.3% | -13.6% | -12.3% | -9.5% | -7.3% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $35.09 | $34.37 | -2.1% | +0.0% | +1.0% | +5.3% | +8.0% | +16.4% |
| Nov 8 | Benchmark | Downgrade | Buy → Hold | — | $33.11 | $33.42 | +0.9% | +4.3% | +6.0% | +6.0% | +7.0% | +11.6% |
| May 5 | Argus | Downgrade | Buy → Hold | — | $59.10 | $58.79 | -0.5% | +3.2% | +3.0% | +4.3% | +1.3% | -0.5% |
| Apr 30 | Chardan Capital | Maintains | Buy → Buy | — | $63.15 | $61.82 | -2.1% | -3.4% | -2.5% | -6.4% | -3.4% | -3.6% |
| Apr 7 | Benchmark | Maintains | Buy → Buy | — | $79.25 | $79.55 | +0.4% | -0.5% | -0.8% | -2.4% | -4.3% | -8.2% |
| Feb 24 | Chardan Capital | Upgrade | Neutral → Buy | — | $93.49 | $98.00 | +4.8% | +5.7% | +3.9% | +2.7% | +9.3% | +6.2% |
| Feb 19 | Chardan Capital | Downgrade | Buy → Neutral | — | $117.06 | $106.98 | -8.6% | -12.0% | -16.5% | -20.1% | -15.6% | -17.0% |
| Jan 8 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $100.77 | $97.08 | -3.7% | -3.5% | -1.9% | +2.6% | +6.8% | +5.2% |
| Jul 31 | Chardan Capital | Maintains | Buy → Buy | — | $97.02 | $103.63 | +6.8% | +14.7% | +21.6% | +26.4% | +38.6% | +30.9% |
| Jul 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $99.47 | $99.92 | +0.5% | +4.8% | +2.6% | -5.4% | -5.5% | -10.6% |
| Jun 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $86.91 | $75.02 | -13.7% | -21.0% | -20.1% | -18.1% | -21.6% | -20.9% |
| May 6 | Argus | Maintains | Buy → Buy | — | $79.51 | $79.50 | -0.0% | -0.0% | -0.3% | +1.5% | +6.3% | +2.5% |
| May 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $73.95 | $76.67 | +3.7% | +6.4% | +7.5% | +7.5% | +7.5% | +7.2% |
| May 1 | Chardan Capital | Maintains | Buy → Buy | — | $73.95 | $76.67 | +3.7% | +6.4% | +7.5% | +7.5% | +7.5% | +7.2% |
| Apr 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $73.95 | $74.00 | +0.1% | +0.0% | +6.4% | +7.5% | +7.5% | +7.5% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $61.44 | $62.66 | +2.0% | -2.5% | -4.9% | -10.0% | -4.5% | -4.3% |
| Sep 12 | Guggenheim | Maintains | Buy → Buy | — | $54.41 | $55.05 | +1.2% | -0.5% | -4.4% | -2.3% | -2.0% | -2.1% |
| Sep 4 | Wells Fargo | Upgrade | Market Perform → Outperform | — | $50.14 | $52.71 | +5.1% | +11.7% | +13.1% | +11.8% | +12.9% | +14.1% |
| Nov 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $63.86 | $63.90 | +0.1% | +1.5% | +5.0% | +7.9% | +8.9% | +5.8% |
| Nov 2 | Goldman Sachs | Upgrade | Neutral → Buy | — | $63.86 | $63.90 | +0.1% | +1.5% | +5.0% | +7.9% | +8.9% | +5.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Zoon Kathryn CDir | — | Sell | 1,057 | $8.97 | $9K | 79,941 | +5.97% | — |
| May 1, 2026 | Zoon Kathryn CDir | — | Sell | 16,145 | $8.36 | $135K | 80,998 | +5.97% | — |
| May 1, 2026 | Dayal Sujata TyagiDir | — | Sell | 980 | $8.94 | $9K | 100,563 | +5.97% | — |
| May 1, 2026 | Dayal Sujata TyagiDir | — | Sell | 12,781 | $8.36 | $107K | 101,543 | +5.97% | — |
| May 1, 2026 | DeGolyer Donald WDir | — | Sell | 954 | $8.96 | $9K | 129,721 | +5.97% | — |
| May 1, 2026 | DeGolyer Donald WDir | — | Sell | 14,527 | $8.36 | $121K | 130,675 | +5.97% | — |
| Apr 30, 2026 | Katkin KeithDir | — | Sell | 15,481 | $8.28 | $128K | 96,294 | +5.97% | — |
8-K · 1.01
! Medium
Emergent Biosolutions, Inc. -- 8-K 1.01: Financing / Debt Agreement
Emergent BioSolutions secured a $150 million credit agreement, providing additional liquidity to support operations and strategic initiatives while potentially reducing reliance on equity financing.
Apr 17
8-K · 5.02
!!! Very High
Emergent Biosolutions, Inc. -- 8-K 5.02: Executive Change
Emergent BioSolutions appoints John D. Fowler as Class II director effective March 1, 2026, adding board expertise to support the company's strategic direction.
Mar 3
8-K · 7.01
! Medium
Emergent Biosolutions, Inc. -- 8-K 7.01: Regulation FD Disclosure
Emergent Biosolutions will host a February 26 earnings call to discuss Q4 and full-year 2025 results, with presentation materials available on its website.
Feb 26
Data updated apr 25, 2026 6:19am
· Source: massive.com